2m 2m 2m 2m 2m 2m 2m
Ligand Pharma (LGND)
NASDAQ
$278.87+$16.69 (+6.37%)
Price as of Jun 23, 2026 6:55 PM EDT- $5.3BMarket Cap
- 128.02%1-Year Change
- BiotechnologyIndustry
Ligand Pharma (LGND)
$278.87+$16.69 (+6.37%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 132.5M -20.70% | 167.1M +27.28% | 131.3M -33.09% | 196.2M -29.19% | |
Cost of Revenue | 227.1M +19.68% | 189.7M +56.17% | 121.5M -37.12% | 193.2M -2.54% | |
Gross Profit | -94.6M +318.26% | -22.6M -330.18% | 9.8M +223.38% | 3.0M -96.15% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -81.2M +278.91% | -21.4M -12.68% | -24.5M -32.00% | -36.1M -47.72% | |
Depreciation and Amortization Expense | 33.8M -4.15% | 35.2M -3.51% | 36.5M -29.13% | 51.5M +0.91% | |
Total Operating Expenses | 319.5M +19.05% | 268.4M +54.00% | 174.3M -33.80% | 263.3M +2.95% | |
Operating Profit | 41.0M +281.38% | -22.6M -289.30% | 11.9M +293.22% | 3.0M -96.15% | |
Interest Income | 13.7M +69.57% | 8.1M +4.46% | 7.7M +276.88% | 2.0M +130.93% | |
Interest Expense | -2.4M +300.00% | -600,000 -8.54% | -656,000 -63.54% | -1.8M -90.83% | |
Interest Income and Expense and Net | 11.3M +51.03% | 7.5M +5.67% | 7.1M +2,756.28% | 247,000 +101.32% | |
Total Nonoperating Income and Expense | 118.0M +369.50% | 25.1M -51.42% | 51.7M +56.84% | 33.0M +204.36% | |
Income before Taxes | 159.0M +6,212.95% | 2.5M -96.04% | 63.7M +76.78% | 36.0M -23.86% | |
Income Taxes | 34.5M +426.82% | 6.5M -33.44% | 9.8M -76.13% | 41.2M +519.00% | |
Extraordinary Items | 0 N/A | 0 N/A | N/A N/A | 0 N/A | |
Net Income | 124.5M +3,186.63% | -4.0M -107.73% | 52.2M +256.33% | -33.4M -158.39% | |
Net Income from Continuing Operations Applicable to Common | 124.5M +3,186.63% | -4.0M -107.49% | 53.8M +1,131.21% | -5.2M -111.03% | |
Basic EPS and Net Income | 6.44 +3,027.27% | -0.22 -107.28% | 3.02 +252.53% | -1.98 -157.56% | |
Diluted EPS and Net Income | 6.13 +2,886.36% | -0.22 -107.48% | 2.94 +248.48% | -1.98 -159.82% | |
Basic Weighted Average Shares | 19.3M +5.73% | 18.3M +5.73% | 17.3M +2.55% | 16.9M +1.43% | |
Diluted Weighted Average Shares | 20.3M +10.96% | 18.3M +3.00% | 17.8M +5.27% | 16.9M -2.19% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 174.9M +141.92% | 72.3M +215.01% | 23.0M -49.00% | 45.0M +130.54% | |
Short-Term Investments | 558.6M +203.82% | 183.9M +24.77% | 147.4M -11.69% | 166.9M -48.11% | |
Cash and Cash Equivalents and Short-Term Investments | 733.5M +186.35% | 256.2M +50.41% | 170.3M -19.62% | 211.9M -37.89% | |
Total Current Assets | 832.3M +151.02% | 331.6M +39.65% | 237.4M -9.93% | 263.6M -43.28% | |
Accumulated Depreciation | 6.6M -20.44% | 8.3M +24.24% | 6.7M -34.27% | 10.1M +16.23% | |
Property and Plant and Equipment and Net | 3.6M -76.40% | 15.1M -3.04% | 15.6M +25.04% | 12.5M -39.14% | |
Total Long-Term Assets | 12.6M +81.72% | 6.9M +16.90% | 5.9M +25.06% | 4.7M +72.78% | |
Total Assets | 1.6B +65.71% | 941.8M +19.63% | 787.2M +3.22% | 762.7M -41.22% | |
Income Taxes Payable | 37.3M +10.48% | 33.7M +6.64% | 31.6M +3.29% | 30.6M -48.19% | |
Total Short-Term Debt | N/A N/A | N/A N/A | 0 -100.00% | 76.7M N/A | |
Total Current Liabilities | 37.4M +0.90% | 37.1M +121.14% | 16.8M -83.02% | 98.8M +137.15% | |
Total Long-Term Debt | 985.6M N/A | N/A N/A | 76.7M N/A | 0 -100.00% | |
Total Long-Term Liabilities | 16.6M -44.87% | 30.2M +8.66% | 27.8M +26.37% | 22.0M -29.09% | |
Total Liabilities | 543.4M +388.10% | 111.3M +29.00% | 86.3M -47.75% | 165.2M -65.33% | |
Retained Earnings | 608.1M +21.87% | 499.0M -0.80% | 503.0M +11.57% | 450.9M +0.39% | |
Total Stockholders Equity | 1.0B +22.49% | 830.4M +18.48% | 700.9M +17.31% | 597.5M -27.24% | |
Total Shares Outstanding | 19.8M +3.50% | 19.1M +8.83% | 17.6M +3.57% | 17.0M +1.10% | |
Cash Flow | |||||
Cash from Operating Activities | 49.4M -49.14% | 97.0M +95.75% | 49.6M -64.04% | 137.8M +74.94% | |
Capital Expenditures | 452,000 -75.18% | 1.8M -48.28% | 3.5M -80.35% | 17.9M +104.58% | |
Cash from Investing Activities | -377.3M +162.64% | -143.7M +1,129.79% | -11.7M -107.14% | 163.6M +436.07% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 428.2M +340.83% | 97.1M +262.04% | -59.9M -78.28% | -276.0M +100.34% | |
Financials Ratio | |||||
Gross Margin | -71.34% +427.44% | -13.53% -280.85% | 7.48% +383.26% | 1.55% -94.56% | |
Operating Margin | 30.94% +328.73% | -13.53% -248.73% | 9.09% +487.63% | 1.55% -94.56% | |
Return on Assets | 9.95% +2,232.63% | -0.47% -106.93% | 6.73% +307.82% | -3.24% -175.38% | |
Return on Equity | 13.47% +2,658.20% | -0.53% -106.55% | 8.03% +270.81% | -4.70% -163.00% | |
Revenue Growth | -20.70% -175.89% | 27.28% +182.44% | -33.09% +13.36% | -29.19% -159.98% | |
Current Ratio | 22.23 +148.77% | 8.93 -36.85% | 14.15 +430.32% | 2.67 -76.08% | |
Cash Ratio | 4.67 +139.76% | 1.95 +42.44% | 1.37 +200.29% | 0.46 -2.77% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | 0.11 -14.80% | 0.13 N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | 0.10 -3.18% | 0.10 N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow